Nurix Therapeutics (NRIX) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Program updates and clinical progress

• NX-5948, a BTK degrader, is advancing toward pivotal trials in 2025, with current focus on CLL and NHL indications.

• IRAK4 degrader for rheumatoid arthritis, partnered with Gilead, is in IND-enabling studies, with an IND filing targeted for 2025.

• STAT6 degrader with Sanofi is approaching development candidate selection, aiming for oral efficacy competitive with Dupixent.

• NX-2127, a dual degrader targeting BTK and IKZF1/3, has shown complete responses in aggressive lymphomas in early trials.

• Multiple undisclosed oncology targets are being pursued in collaboration with major pharmaceutical partners.

Clinical data and efficacy highlights

• NX-5948 demonstrated potent activity against BTK resistance mutations, with a 70% response rate in heavily pretreated CLL patients.

• The drug is well-tolerated, with patients remaining on therapy and showing significant lymph node reduction.

• Case studies highlight efficacy in CNS-involved CLL and patients refractory to multiple prior therapies, including CAR T.

• No genotypic profile has been linked to intrinsic resistance to NX-5948, supporting broad applicability.

• Fast track status has been granted for third-line CLL, with plans for randomized trials in earlier lines.

Mechanism of action and safety

• NX-5948 is a bifunctional, oral molecule that catalytically degrades BTK, overcoming limitations of inhibitors.

• The degrader approach targets both kinase and scaffolding functions, potentially replacing BTK inhibitors in a $9B+ market.

• Proteomic analysis shows high specificity, with side effects limited to BTK target engagement and no off-target degradation.

• Lower drug levels are required compared to inhibitors, suggesting a favorable safety profile.

• The approach is being explored for autoimmune diseases, aiming for improved efficacy over current therapies.